Virus-Boosted immune cells take on tough melanoma
NCT ID NCT06961786
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new approach for advanced melanoma that has not responded to standard treatments. Nine patients will receive a modified virus (TILT-123) designed to deliver immune-boosting signals directly into tumors, along with their own tumor-fighting immune cells (TILs) and chemotherapy. The main goal is to check safety and tolerability, not yet to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TILT-123 (a modified virus that delivers TNFa and IL-2) combined with tumor-infiltrating lymphocytes (TILs) and chemotherapy (cyclophosphamide and fludarabine)
What this could lead to
If this approach is safe and shows promise, it could point toward a new combination therapy for advanced melanoma that has stopped responding to other treatments.
What could go wrong
This is a very early phase 1 trial with only 9 people, focused on safety not effectiveness. The virus and cell therapy may cause serious side effects, and the treatment may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University
Copenhagen, Denmark